Speaker: Helena Geys, Janssen Pharmaceutica and Philip Jarvis, AstraZeneca
An assessment of the statistical methods used to analyse toxicology studies
Co-authors: Jim Saul, Mike Aylott, Simon Bate and John Sherington;
Pharmaceutical Statistics, Volume 10, Issue 6, Pages 477-484, November/December 2011 Abstract | Paper+ | Slides
Biomarker SIG
Speaker: Martin Jenkins, AstraZeneca and Chris Harbron, AstraZeneca
A statistician's perspective on biomarkers in drug development
Co-authors: Aiden Flynn, Trevor Smart, Tony Sabin, Jayantha Ratnayake, Paul Delmar, Athula Herath, Philip Jarvis and James Matcham;
Pharmaceutical Statistics, Volume 10, Issue 6, Pages 494-507, November/December 2011 Abstract | Paper+ | Slides
+ Papers available to view from 20th September 2012 to 18th October 2012.
For a flier advertising the event, please click here.
Scientific Meetings
Journal Club - PSI’s Special Interest Groups (SIGs)
Speaker: Helena Geys, Janssen Pharmaceutica and Philip Jarvis, AstraZeneca
An assessment of the statistical methods used to analyse toxicology studies
Co-authors: Jim Saul, Mike Aylott, Simon Bate and John Sherington;
Pharmaceutical Statistics, Volume 10, Issue 6, Pages 477-484, November/December 2011 Abstract | Paper+ | Slides
Biomarker SIG
Speaker: Martin Jenkins, AstraZeneca and Chris Harbron, AstraZeneca
A statistician's perspective on biomarkers in drug development
Co-authors: Aiden Flynn, Trevor Smart, Tony Sabin, Jayantha Ratnayake, Paul Delmar, Athula Herath, Philip Jarvis and James Matcham;
Pharmaceutical Statistics, Volume 10, Issue 6, Pages 494-507, November/December 2011 Abstract | Paper+ | Slides
+ Papers available to view from 20th September 2012 to 18th October 2012.
For a flier advertising the event, please click here.
Training Courses
Journal Club - PSI’s Special Interest Groups (SIGs)
Speaker: Helena Geys, Janssen Pharmaceutica and Philip Jarvis, AstraZeneca
An assessment of the statistical methods used to analyse toxicology studies
Co-authors: Jim Saul, Mike Aylott, Simon Bate and John Sherington;
Pharmaceutical Statistics, Volume 10, Issue 6, Pages 477-484, November/December 2011 Abstract | Paper+ | Slides
Biomarker SIG
Speaker: Martin Jenkins, AstraZeneca and Chris Harbron, AstraZeneca
A statistician's perspective on biomarkers in drug development
Co-authors: Aiden Flynn, Trevor Smart, Tony Sabin, Jayantha Ratnayake, Paul Delmar, Athula Herath, Philip Jarvis and James Matcham;
Pharmaceutical Statistics, Volume 10, Issue 6, Pages 494-507, November/December 2011 Abstract | Paper+ | Slides
+ Papers available to view from 20th September 2012 to 18th October 2012.
For a flier advertising the event, please click here.
Journal Club
Journal Club - PSI’s Special Interest Groups (SIGs)
Speaker: Helena Geys, Janssen Pharmaceutica and Philip Jarvis, AstraZeneca
An assessment of the statistical methods used to analyse toxicology studies
Co-authors: Jim Saul, Mike Aylott, Simon Bate and John Sherington;
Pharmaceutical Statistics, Volume 10, Issue 6, Pages 477-484, November/December 2011 Abstract | Paper+ | Slides
Biomarker SIG
Speaker: Martin Jenkins, AstraZeneca and Chris Harbron, AstraZeneca
A statistician's perspective on biomarkers in drug development
Co-authors: Aiden Flynn, Trevor Smart, Tony Sabin, Jayantha Ratnayake, Paul Delmar, Athula Herath, Philip Jarvis and James Matcham;
Pharmaceutical Statistics, Volume 10, Issue 6, Pages 494-507, November/December 2011 Abstract | Paper+ | Slides
+ Papers available to view from 20th September 2012 to 18th October 2012.
For a flier advertising the event, please click here.
Webinars
Journal Club - PSI’s Special Interest Groups (SIGs)
Speaker: Helena Geys, Janssen Pharmaceutica and Philip Jarvis, AstraZeneca
An assessment of the statistical methods used to analyse toxicology studies
Co-authors: Jim Saul, Mike Aylott, Simon Bate and John Sherington;
Pharmaceutical Statistics, Volume 10, Issue 6, Pages 477-484, November/December 2011 Abstract | Paper+ | Slides
Biomarker SIG
Speaker: Martin Jenkins, AstraZeneca and Chris Harbron, AstraZeneca
A statistician's perspective on biomarkers in drug development
Co-authors: Aiden Flynn, Trevor Smart, Tony Sabin, Jayantha Ratnayake, Paul Delmar, Athula Herath, Philip Jarvis and James Matcham;
Pharmaceutical Statistics, Volume 10, Issue 6, Pages 494-507, November/December 2011 Abstract | Paper+ | Slides
+ Papers available to view from 20th September 2012 to 18th October 2012.
For a flier advertising the event, please click here.
Careers Meetings
Journal Club - PSI’s Special Interest Groups (SIGs)
Speaker: Helena Geys, Janssen Pharmaceutica and Philip Jarvis, AstraZeneca
An assessment of the statistical methods used to analyse toxicology studies
Co-authors: Jim Saul, Mike Aylott, Simon Bate and John Sherington;
Pharmaceutical Statistics, Volume 10, Issue 6, Pages 477-484, November/December 2011 Abstract | Paper+ | Slides
Biomarker SIG
Speaker: Martin Jenkins, AstraZeneca and Chris Harbron, AstraZeneca
A statistician's perspective on biomarkers in drug development
Co-authors: Aiden Flynn, Trevor Smart, Tony Sabin, Jayantha Ratnayake, Paul Delmar, Athula Herath, Philip Jarvis and James Matcham;
Pharmaceutical Statistics, Volume 10, Issue 6, Pages 494-507, November/December 2011 Abstract | Paper+ | Slides
+ Papers available to view from 20th September 2012 to 18th October 2012.
For a flier advertising the event, please click here.
Upcoming Events
PSI Webinar: Development of Gene Therapies: Strategic, Scientific, Regulatory and Access Considerations
This webinar will cover the history of cell/gene therapy, major regulatory advances, the role of quantitative scientists in drug development of these novel therapeutics, and discuss opportunities for innovation and product advancement.
Joint PSI/EFSPI Visualisation SIG 'Wonderful Wednesday' Webinars
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
PSI Introduction to Industry Training (ITIT) Course - 2024/2025
An introductory course giving an overview of the pharmaceutical industry and the drug development process as a whole, aimed at those with 1-3 years' experience. It comprises of six 2-day sessions covering a range of topics including Research and Development, Toxicology, Data Management and the Role of a CRO, Clinical Trials, Reimbursement, and Marketing.
PSI Training Course: Regulatory Guidelines for Statisticians
This 2-day course is designed to provide a comprehensive understanding of the regulatory guidelines affecting statisticians in the pharmaceutical industry, including the latest updates in the field. The course will cover key International Council for Harmonisation (ICH) guidelines and other key regional regulatory agency documents.
In this event, we’ll start with a general introduction to hierarchical composite endpoints and an overview of common analysis methods including win ratio, win odds, and net benefit. Then, the practical considerations will be illustrated through case studies from clinical trials in heart failure and chronic kidney disease. We conclude with a discussion and a Q&A.
Joint PSI/EFSPI Pre-Clinical SIG Webinar: Virtual Control Groups in Toxicity Studies
Lea Vaas will present how replacement of concurrent control animals by Virtual Control Groups (VCGs) in systemic toxicity studies may help in contributing to the 3R's principle of animal experimentation: Reduce, Refine, Replace.
This networking event is aimed at statisticians that are new to the pharmaceutical industry who wish to meet colleagues from different companies and backgrounds.
Statisticians in the Pharmaceutical Industry Executive Office: c/o MCI UK Ltd | Unit 24/22 South | Building 4000 | Langstone Park| Langstone Road | Havant | PO9 1SA | UK